138 related articles for article (PubMed ID: 11144542)
1. The cost-effectiveness of screening for latent tuberculosis infection.
Taylor Z
Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S127-33. PubMed ID: 11144542
[No Abstract] [Full Text] [Related]
2. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
Plunkett BA; Grobman WA
Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
[TBL] [Abstract][Full Text] [Related]
3. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.
Khan K; Muennig P; Behta M; Zivin JG
N Engl J Med; 2002 Dec; 347(23):1850-9. PubMed ID: 12466510
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
6. Screening for familial intracranial aneurysms: decision and cost-effectiveness analysis.
Takao H; Nojo T; Ohtomo K
Acad Radiol; 2008 Apr; 15(4):462-71. PubMed ID: 18342771
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of isoniazid chemoprevention in close contacts.
Diel R; Nienhaus A; Schaberg T
Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
[TBL] [Abstract][Full Text] [Related]
8. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
10. [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings].
Yoshiyama T
Kekkaku; 2000 Nov; 75(11):629-41. PubMed ID: 11140086
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
Kobayashi T; Goto R; Ito K; Mitsumori K
Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic screening for gastric cancer.
Dan YY; So JB; Yeoh KG
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly.
Marchand R; Tousignant P; Chang H
Int J Epidemiol; 1999 Jun; 28(3):563-70. PubMed ID: 10405865
[TBL] [Abstract][Full Text] [Related]
16. Management of latent tuberculosis infection in immigrants.
Menzies D; Schwartzman K
N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12661572
[No Abstract] [Full Text] [Related]
17. Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet.
Hershcovici T; Leshno M; Goldin E; Shamir R; Israeli E
Aliment Pharmacol Ther; 2010 Apr; 31(8):901-10. PubMed ID: 20096017
[TBL] [Abstract][Full Text] [Related]
18. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis.
Salpeter SR; Salpeter EE
Infect Control Hosp Epidemiol; 2004 Dec; 25(12):1056-61. PubMed ID: 15636292
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer.
Dewilde S; Anderson R
Med Decis Making; 2004; 24(5):486-92. PubMed ID: 15358997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
